Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer

Quality of Life Research

Volumn 22, Issue 8, 2013, Pages 2143-2150

  Barney, Bradley J ^a   Wang, Xin Shelley ^b   Lu, Charles ^b   Liao, Zhongxing ^b   Johnson, Valen E ^b,c   Cleeland, Charles S ^b   Mendoza, Tito R ^b  

^a KENNESAW STATE UNIVERSITY   (Georgia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Interference; Lung cancer; Symptoms

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; HEALTH STATUS INDICATOR; HEALTH SURVEY; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SELF REPORT; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; SYMPTOM ASSESSMENT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEALTH STATUS INDICATORS; HEALTH SURVEYS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SELF REPORT; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; SYMPTOM ASSESSMENT;

EID: 84889092655     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-013-0356-2     Document Type: Article

References (34)

1. Cella, D.; Riley, W.; Stone, A.; Rothrock, N.; Reeve, B.; Yount, S.; et al. (2010). The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. Journal of Clinical Epidemiology, 63(11), 1179-1194.
2. US Food and Drug Administration. (2009). Guidance for industry. Patient-reported outcome measures: Use in medical product development to support labeling claims. U.S. Department of Health and Human Services. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM071975.pdf. Accessed 31 July 2012.
3. Basch, E. M.; Reeve, B. B.; Mitchell, S. A.; Clauser, S. B.; Minasian, L.; Sit, L.; et al. (2011). Electronic toxicity monitoring and patient-reported outcomes. Cancer Journal (Sudbury, Mass.), 17(4), 231-234.
4. Cleeland, C. S.; Mendoza, T. R.; Wang, X. S.; Chou, C.; Harle, M. T.; Morrissey, M.; et al. (2000). Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer, 89(7), 1634-1646.
5. Cella, D. F.; Tulsky, D. S.; Gray, G.; Sarafian, B.; Linn, E.; Bonomi, A.; et al. (1993). The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570-579.
6. Aaronson, N. K.; Ahmedzai, S.; Bullinger, M.; Crabeels, D.; Estapè, J.; Filiberti, A.; et al. (1991). The EORTC core quality of life questionnaire: Interim results of an international field study. In D. Osoba (Ed.), Effect of cancer on quality of life (pp. 185-203). Boca Raton, FL: CRC Press.
7. Aaronson, N. K.; Ahmedzai, S.; Bergman, B.; Bullinger, M.; Cull, A.; Duez, N. J.; et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.
8. Ware, J. E, Jr, & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473-483.
9. Ware, J, Jr, Kosinski, M.; & Keller, S. D. (1996). A 12-Item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220-233.
10. Quinten, C.; Coens, C.; Mauer, M.; Comte, S.; Sprangers, M. A.; Cleeland, C.; et al. (2009). Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncology, 10(9), 865-871.
11. Sloan, J. A.; Zhao, X.; Novotny, P. J.; Wampfler, J.; Garces, Y.; Clark, M. M.; et al. (2012). Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. Journal of Clinical Oncology, 30(13), 1498-1504.
12. Wang, X. S.; Shi, Q.; Lu, C.; Basch, E. M.; Johnson, V. E.; Mendoza, T. R.; et al. (2010). Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer, 116(1), 137-145.
13. Mauer, M.; Bottomley, A.; Coens, C.; & Gotay, C. (2008). Prognostic factor analysis of health-related quality of life data in cancer: A statistical methodological evaluation. Expert Review of Pharmacoeconomics & Outcomes Research, 8(2), 179-196.
14. Armstrong, T. S.; Vera-Bolanos, E.; Gning, I.; Acquaye, A.; Gilbert, M. R.; Cleeland, C.; et al. (2011). The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer, 117(14), 3222-3228.
15. Hoang, T.; Xu, R.; Schiller, J. H.; Bonomi, P.; & Johnson, D. H. (2005). Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. Journal of Clinical Oncology, 23(1), 175-183.
16. Ikeda, M.; Okada, S.; Tokuuye, K.; Ueno, H.; & Okusaka, T. (2001). Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemo radiotherapy. Cancer, 91(3), 490-495.
17. Kim, J. G.; Ryoo, B. Y.; Park, Y. H.; Kim, B. S.; Kim, T. Y.; Im, Y. H.; et al. (2008). Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemotherapy and Pharmacology, 61(2), 301-307.
18. Kim, T. J.; Song, S.; Kim, C. K.; Kim, W. Y.; Choi, C. H.; Lee, J. H.; et al. (2007). Prognostic factors associated with brain metastases from epithelial ovarian carcinoma. International Journal of Gynecological Cancer, 17(6), 1252-1257.
19. Park, S. R.; Kook, M. C.; Choi, I. J.; Kim, C. G.; Lee, J. Y.; Cho, S. J.; et al. (2010). Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemotherapy and Pharmacology, 65(3), 579-587.
20. Cleeland, C. S.; Mendoza, T. R.; Wang, X. S.; Woodruff, J. F.; Palos, G. R.; Richman, S. P.; et al. (2011). Levels of symptom burden during chemotherapy for advanced lung cancer: Differences between public hospitals and a tertiary cancer center. Journal of Clinical Oncology, 29(21), 2859-2865.
21. Mendoza, T. R.; Wang, X. S.; Lu, C.; Palos, G. R.; Liao, Z.; Mobley, G. M.; et al. (2011). Measuring the symptom burden of lung cancer: The validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist, 16(2), 217-227.
22. Sloan, J. A.; Aaronson, N.; Cappelleri, J. C.; Fairclough, D. L.; & Varricchio, C. (2002). Assessing the clinical significance of single items relative to summated scores. Mayo Clinic Proceedings, 77(5), 479-487.
23. Harrell, F. E, Jr, Lee, K. L.; Califf, R. M.; Pryor, D. B.; & Rosati, R. A. (1984). Regression modelling strategies for improved prognostic prediction. Statistics in Medicine, 3(2), 143-152.
24. R Documentation. (2012). Compute a concordance measure. http://stat.ethz.ch/R-manual/R-patched/library/survival/html/survConcordance. html. Accessed 31 July 2012.
25. Burr, D. (1994). A comparison of certain bootstrap confidence intervals in the Cox model. Journal of the American Statistical Association, 89(428), 1290-1302.
26. Sauerbrei, W.; & Schumacher, M. (1992). A bootstrap resampling procedure for model building: Application to the Cox regression model. Statistics in Medicine, 11(16), 2093-2109.
27. R Core Team. (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org. Accessed 23 Aug 2012.
28. Therneau, T. (2012). A package for survival analysis in S. R package version 2.36-14. The R Project for Statistical Computing. http://cran.r-project. org/web/packages/survival//survival.pdf. Accessed 23 Aug 2012.
29. R Documentation. (2012). Compute a survival curve from a Cox model. http://stat.ethz.ch/R-manual/R-patched/library/survival/html/survfit.coxph.html. Accessed 31 July 2012.
30. Altman, D. G.; & Andersen, P. K. (1989). Bootstrap investigation of the stability of a Cox regression model. Statistics in Medicine, 8(7), 771-783.
31. Ohman, E. M.; Granger, C. B.; Harrington, R. A.; & Lee, K. L. (2000). Risk stratification and therapeutic decision making in acute coronary syndromes. The Journal of the American Medical Association, 284(7), 876-878.
32. Braun, D. P.; Gupta, D.; & Staren, E. D. (2011). Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer, 11, 353.
33. Visbal, A. L.; Williams, B. A.; Nichols, F. C, I. I. I.; Marks, R. S.; Jett, J. R.; Aubry, M. C.; et al. (2004). Gender differences in non-small-cell lung cancer survival: An analysis of 4,618 patients diagnosed between 1997 and 2002. The Annals of Thoracic Surgery, 78(1), 209-215.
34. Gotay, C. C.; Kawamoto, C. T.; Bottomley, A.; & Efficace, F. (2008). The prognostic significance of patient-reported outcomes in cancer clinical trials. Journal of Clinical Oncology, 26(8), 1355-1363.